RetaCalc
Protocol library
SingleNot ApprovedEarly HumanSourced

Selank

A synthetic heptapeptide studied in small human and laboratory studies, with limited internationally accessible clinical evidence and no UK marketing authorisation.

Evidence context, not a personal protocol

Quantities below reproduce study or label context. They do not assess suitability, product equivalence or individual risk.

Regimens studied

Adults enrolled in a small comparative anxiety study

Investigators used an intranasal study preparation under a research protocol

The abstract does not justify translating the study preparation into a self-directed research-vial dose.

View source

Evidence summary

The available literature includes a small clinical report and preclinical mechanistic work. That is not comparable to a modern regulatory dossier or large controlled trial programme.

Evidence limits

Claims about long-term safety, dependence, cognitive enhancement or broad anxiety treatment should not be made from the current evidence base.

Warnings and contraindications

Published human evidence is small and does not establish a UK-authorised regimen.
Mechanistic animal or gene-expression findings cannot establish clinical efficacy.